10:18 AM EDT, 06/20/2024 (MT Newswires) -- Kyverna Therapeutics ( KYTX ) said Thursday the US Food and Drug Administration has cleared the company's Investigational New Drug application for KYV-101, a candidate for therapy to treat stiff-person syndrome to be used a Kyverna trial.

SPS is a rare, progressive autoimmune disorder that causes severe muscle stiffness in the torso, arms, and legs, affecting mobility and the ability to walk, the company said.

KYV-101, an autologous anti-CD19 CAR T-cell therapy, is currently in phase 1/2 trials in the US and Germany for patients with lupus nephritis and phase 2 trials for rheumatology and neurology autoimmune diseases, Kyverna said.

Shares of Kyverna were up 8.4% in recent Thursday trading.

Price: 8.07, Change: +0.63, Percent Change: +8.44